Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hereditary medullary thyroid carcinoma--genotype-phenotype characterization].

K Frank-Raue1, C Heimbach, S Rondot

  • 1Endokrinologische Gemeinschaftspraxis, Heidelberg. raue-heidelberg@t-online.de

Deutsche Medizinische Wochenschrift (1946)
|September 26, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrasound measurement technique for the single-turn-coil magnets.

The Review of scientific instruments·2021
Same author

[Neuroendocrine tumors : Classification, clinical presentation and imaging].

Der Radiologe·2019
Same author

Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades.

Clinical endocrinology·2017
Same author

A Novel Mutation of the Calcium Sensing Receptor Gene in a Franconian Kindred: Heterozygous Mutation c.1697_1698delTG Exon 6.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2016
Same author

Evaluation of a Recently Established Test for Familial Hyperaldosteronism Type 1.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2016
Same author

Long-Term Follow-Up and Treatment of Postoperative Permanent Hypoparathyroidism in Patients with Medullary Thyroid Carcinoma: Differences in Complete and Partial Disease.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2016

Medullary thyroid carcinoma (MTC) patients with mutations in exons 13-15 show a later onset and slower progression than those with exon 11 mutations. This finding impacts recommendations for prophylactic surgery timing and extent in hereditary MTC.

Area of Science:

  • Oncology
  • Genetics
  • Endocrinology

Background:

  • Hereditary medullary thyroid carcinoma (MTC) arises from germline mutations in the RET proto-oncogene.
  • Specific RET mutations correlate with distinct clinical syndromes like MEN 2A and MEN 2B.
  • Variability in MTC development and aggressiveness across different cancer syndromes is suggested.

Purpose of the Study:

  • To compare the clinical phenotype of patients with RET mutations in exons 13-15 versus exon 11 (codon 634).
  • To evaluate potential therapeutic implications based on genotype-phenotype correlations.
  • To inform clinical management strategies for hereditary MTC.

Main Methods:

  • Phenotypic comparison of 47 patients with exon 13-15 mutations against 66 patients with exon 11 (codon 634) mutations.

Related Experiment Videos

  • Subdivision of patients into index and screening cohorts for detailed analysis.
  • Analysis of age at diagnosis, tumor stage, cure rates, and mortality.

    • Main Results:

    • Index patients with exon 13-15 mutations (codons 790, 791, 804, 891) had a significantly later age at diagnosis (50 vs. 31 years) compared to codon 634 mutation carriers.
    • Favorable tumor stage at operation, better cure rates (56% vs. 38%), and lower death rates were observed in the exon 13-15 group.
    • No significant differences in age, tumor stage, cure, or death rates were found between the groups in screening patients.

    Conclusions:

    • RET mutations in codons 790, 791, 804, and 891 are associated with a later onset and more indolent course of MTC compared to codon 634 mutations.
    • These genotype-phenotype differences necessitate consideration when determining the optimal timing and extent of prophylactic surgery.
    • Personalized management strategies based on specific RET mutation profiles are crucial for hereditary MTC.